Bioblast announces results of trehalose clinical study
Bioblast Pharma announced results of a double-blind, placebo-controlled pharmacokinetic study of intravenous trehalose 90mg/mL in healthy volunteers. The primary objective of the study was to establish safety and tolerability of escalating doses of trehalose. October 24, 2016